Measuring Performance as a Dependent Variable of Patent Management Maturity

R. Hilarius

July 15, 2013
Measuring Performance as a Dependent Variable of Patent Management Maturity

R. Hilarius

Universiteit Twente, Drienerlolaan 5, 7522 NB, Enschede, Netherlands

Abstract

In this article the effect of the Strategic Patent Management Maturity will be assessed by using the patent h-index. The author will start by discussing the typology for assessing the strategic patent management maturity. In detail the attributed function Liability will be discussed regarding the results from the case-study and an alternative implementation is proposed. Next the similarities and differences of inventing and innovating are discussed because these concepts are often applied incorrectly. While the correct use can be of importance to make essential differences clear. To assess the Strategic Patent Management Maturity using patents, different options are discussed regarding the quantity and quality of patents. The patent h-index is chosen as the best indicator representing the inventive impact of an organization’s patent portfolio. Because of the strong influence of sectoral differences on the propensity to patent of an organization and the representation of the patent portfolio as sample of inventive output, the use of propensity to patent as intervening variable is discussed. The operationalization of the used indicators is discussed and the determination of the h-index is worked out, using the biopharmaceutical and biotechnological companies from van Reekum’s pilot and case study. We conclude by discussing the found results.

Keywords: Invention, Innovation, Patent Management Maturity, h-index, Patent, Propensity to Patent

1. introduction

In this article I attempt to make a contribution to the Strategic Patent Management typology developed by van Reekum. Following the results from Kern and van Reekum (2012), I will suggest a different and more general approach for the liability attribute of patents. Using this typology as my starting point I will build a conceptual model and use insights from the field of scientometrics to suggest an independent variable to measure performance differences between the four categories as developed by van Reekum.

2. A typology for assessing strategic patent management maturity

Based on Ackoff’s categories of strategic planning attitudes (Ackoff, 1981), Kern and van Reekum developed four attitudes that are applicable in the strategic patent management practice. In his book Ackoff develops four categories based on the attitudes towards planning. He develops them by looking at the distinctive differences of their temporal orientation and planning posture, see table 1 (Ackoff, 1981, p. 52-65).

Although Kern and van Reekum do not use a form of temporal orientation, they develop four planning attitudes for patent management based on Ackoff’s planning attitudes. Each representing an increasing level of activeness. Van Reekum however, does this regarding eight patent functions. In analogue to Ackoff, van Reekum distinguishes the following four planning attitudes for patent management: Inactive, Reactive, Active and Proactive. The eight functions are divided in two categories; the inherent functions and the attributed functions. The inherent functions are the functions of patents as intended by the designers of the patent system. The attributed functions are the functions, other than the inherent functions, assigned to patents by managers for corporate purposes. The functions and its attributes...
Temporal Orientation Types of planning

<table>
<thead>
<tr>
<th>Reactive</th>
<th>Past</th>
<th>Tactical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactive</td>
<td>Present</td>
<td>Operational</td>
</tr>
<tr>
<td>Preactive</td>
<td>Future</td>
<td>Strategic</td>
</tr>
<tr>
<td>Interactive (Proactive)</td>
<td>All</td>
<td>Normative</td>
</tr>
</tbody>
</table>

Table 1: Ackoff’s categories of strategic planning attitudes

are summarized in table 2 and will not be discussed in detail here. When looking at the four different attitudes and their eight functions one has to realize that their borders are not absolute. What Ackoff says about his planning orientations can also be regarded in this case: “The four basic planning orientations are like the primary colors; they seldom appear in their pure form. Most of the planning we see, like colors, are mixtures; nevertheless, they are usually dominated by one of the four pure types.” (Ackoff, 1981, p. 53)

From the pilot study performed by Kern and van Reekum the relevance of seven of the eight functions were confirmed, leaving liability unconfirmed. In their article Kern and van Reekum discuss this and note that the financial meaning of patent liability is not applicable in the Netherlands because the Dutch tax policy prohibits sale & lease-back constructions with patents (Hulsink and Schenk, 2002). However, patent liability in the sense of its legal meaning, the consequence of infringement, is still of importance. With the experience gained from the pilot and case study the liability function is going to be developed in an alternative way.

2.1. Liability

In van Reekum’s typology, liability is considered to be ambiguous, taking into account it’s financial as well as its legal meaning. In the Pilot study conducted the financial aspect of this function was not confirmed. Presumably because the applied definition was not applicable in the Netherlands. We depart from van Reekums elaboration and take a different approach to this function. The foundations for the new approach are the concepts of Freedom to Operate (FtO) and Liability of Newness (LoN). Freedom to Operate is not new in the field of intellectual property. It essentially denotes the (legal) freedom one has before risking infringement. Or as Sandal and Kumar put it: “FtO is essentially a legal concept, which connotes absence of any third party valid intellectual property right (IPR) claims against a particular commercial operation” (Sandal and Kumar, 2011, p. 204). To determine the FtO, a prior art search has to be carried out. This may be done for various reasons; determining the patentability of an invention, ground of patent invalidation or possibility to proceed with the research, development and/or commercial production, marketing or use of a new product or process. (Sandal and Kumar, 2011) The results of this FtO analysis should make clear if there is a liability or an opportunity.

The second concept used to elaborate on liability is Liability of Newness (LoN). Generally this concept is used as introduced by Stinchcombe (1965), to describe a greater mortality risk of new organizations compared to established organizations. However this concept can be applied to inventions instead of organizations, essentially describing aspects of the liability function. The notion here is that an invention carries inherent risks. It starts with the question if an invention has the potential to become an innovation and if so, if it can be patented or otherwise protected. Any technology that has been developed to this point already needed a certain amount of effort (time, money, R&D). This initial investment constitutes the inherent technological risk of an invention. To further illustrate this, the concepts of incremental and radical innovation can be considered. The framework these concepts are part of consists of two dimensions where innovation can find place. It also assesses different, not always controllable, forces that influence the possible success of the innovation, or to put it differently, the risks there are of an invention becoming an innovation.

Not included in the concepts of FtO and LoN is a form of financial liability as used by van Reekum. With this third form of liability he includes the (international) practice of using patents as collateral to obtain a loan, placing a lien on the patent. The reason that this liability was not confirmed in the
Inherent functions

Incentive
This function represents the patent as an input motivator to R&D efforts

Appropriation
This function represents the patent as a mechanism providing functional exclusiveness to an invention

Protection
This function represents the patent as the legal ability to exclude others from gaining returns on investments the proprietor made to create the invention.

Dissemination
This is about the patent as a source of information open to rival companies (as a consequence of being a publication), often inducing circumvention.

Attributed functions

Liability
The financial meaning of patent liability is that of securing a loan.

Portfolio component
The patent considered as part of a set of more or less related proprietary technologies that serve the corporate future.

Asset
The patent as a financially valued means of producing gains to the owner.

Performance indicator
The patent considered as an informational medium to represent the company’s research performance and technology marketing potential.

Table 2: Patent functions. Kern and van Reekum (2012)

pilot study is because it is prohibited by Dutch policy. Internationally however this practice is reality and thus it needs to be included.

Now that the liability function is explained in a broader scope to cover all the aspects, it is necessary to operationalize this to the four attitudes of the typology, see table 3.

3. Invention or innovation?

With the adjustments done to the strategic patent management attributes by reevaluating the Liability function we now have a complete framework to use as an independent variable for evaluating a firm’s attitude regarding patent management. To do more than merely categorize firms, it is necessary to develop a dependent variable. Although scholars have written a lot about a firms performance, in most cases financial performance, there is not much written about the performance of a firms Intellectual Property Management (IPM). There is no such thing as a generally accepted way to measure the effectiveness of a firms IPM. Therefore it is necessary to develop our own performance variable.

We start by making clear what we mean when talking about inventions and innovations. When discussing patent management and performance, often the terms invention and innovation are concerned. In practice the difference between inventing and innovating is often unclear and the words are used as synonyms. It even went so far that innovation became a buzzword, used by managers (and everyone else) for everything that was even remotely new (to them). In our discussion the difference between an invention and innovation is however very important.

As starting point we use the definition used by Tidd et al. (2005). Tidd describes that inventing is only the beginning in the innovation process, there are enough good ideas available but only a few of them become true innovations. The step from invention to innovation is by no means automatic, as already discussed by Maclaurin (1953). For example: Often researchers are great inventors but, more often than not, poor innovators. Or to use an example from Tidd: “Edison appreciated better than most that the real challenge in innovation was not invention –coming up with good ideas –but making them work technically and commercially.” (Tidd et al., 2005, p. 65). Regarding innovation, R&D and marketing are two sides of the same coin. In addition it is worth mentioning that the size of the invention (the technological leap forward) is not necessarily proportional to the size of the innovation. An incremental improvement of a product may become a big innovation and a revolutionary new product may never sell a single unit. Inventing and innovating both can be done in incremental to radical proportions.

Next there is the relationship between inventing, innovating and patenting. Based on the discussion
<table>
<thead>
<tr>
<th></th>
<th>Inactive</th>
<th>Reactive</th>
<th>Active</th>
<th>Pro-active</th>
</tr>
</thead>
<tbody>
<tr>
<td>FtO:</td>
<td>When infringement is claimed the activities are stopped and/or the litigation is resolved by settlement.</td>
<td>An FtO is conducted after infringement is claimed to prevent future litigation.</td>
<td>A FtO search is done. When (possible) infringement is found the problem is circumvented or the project canceled.</td>
<td>A FtO search is done. When (possible) infringement is found, circumvention is an option as well as acquiring a license or patent.</td>
</tr>
<tr>
<td>LoN:</td>
<td>R&amp;D in new products is avoided. The organizations efforts are aimed at improving and evolving the proven products.</td>
<td>R&amp;D for new products is started when technological rivalry is assessed on the basis of patent info</td>
<td>Alternatives assessed before investing</td>
<td>Initial (R&amp;D) costs are seen as investments, not as costs. The (strategic) development of new products is done according the product life-cycle.</td>
</tr>
<tr>
<td>Financial:</td>
<td>Does not use a patent as collateral to obtain a loan.</td>
<td>The patent(portfolio) is valuated, but is not used as collateral</td>
<td>On request of a financier a patent is used to obtain a loan. (exclusively)</td>
<td>The organization uses a patent to obtain a loan. (exclusively)</td>
</tr>
</tbody>
</table>

Table 3: Liability in the typology

---

Figure 1: A generalized picture of the relationship between patenting, invention and innovation. The sizes of the different parts of the figure are of course arbitrary chosen and may vary across sectors and in time. (Basberg, 1987)
of this subject by MacLaurin (1953), Basberg (1987) represents this graphically as can be seen in figure 1.

Patented inventions and innovations only make up a small part of all inventions and patented innovations an even smaller part. Besides the relationship between inventions, innovations and patents, figure 1 tries to make clear that the use of patent statistics rests on the assumption that they are somehow reflecting inventive and innovative activity (Basberg, 1987).

4. Quantity and Quality

Now we have clarified the distinction between inventions and innovations we are going to continue with patents and performance. For many years scholars analyzed patent data in an attempt to make predictions based on it, or otherwise learn and draw conclusions from it. Patent law and thus patents came into existence with the purpose to give an inventor an exclusive right to commercialize its invention during a limited time. This is of importance because it stimulates to invest in the development of new ideas. The thought being that if everyone could simply copy a successful idea, no one would want to invest in development any more. This basic principle makes clear why patents are an intermediate product of inventions with potential. Because of this it is plausible to assume patents contain information from the creative processes going on in firms, organizations or persons. However a relationship between patents and a firm’s (financial) performance is not as obvious as one may think. In his article, Holger Ernst states the following: “On the firm level in particular, the question of whether there is a correlation between patents and financial performance remains unresolved” He adds: “Some empirical studies — recent ones, in particular — establish a positive correlation between a firm’s patent situation and its competitive position.” Finally in his conclusion he states: “From a theoretical point of view with regard to further empirical patent research, we were able to show in addition to the findings of previous cross-section analyses a positive correlation between patent applications and subsequent changes in economic performance variables on the firm level” (Holger, 2001). From this we can conclude that patents may not be directly correlated to a firm’s financial performance, but they do seem to be able to incorporate some kind of performance. So for what are patents a suitable indicator?

In essence patents are an intermediate product resulting from inventive activities. This makes them inherently more suitable to assess these inventive activities than innovation. The process in which an invention becomes an innovation depends on far more than a firm’s IPM, which does govern the conditions regarding inventing and patent awareness.

As our starting point we are going to look at the article from Hagedoorn and Cloodt (2003). In this article, Hagedoorn and Cloodt discuss several indicators used to measure innovative performance and what the added value is in using more than one indicator. Interesting for us is that in relation to innovative performance they also discuss the concept of inventive performance. In their article they state the following: “We define inventive performance as the achievements of companies in terms of ideas, sketches, models of new devices, products, processes and systems. As discussed below, inventive performance is frequently measured in the context of patents where both raw counts of patents and patent citations are taken as the actual measures.” (Hagedoorn and Cloodt, 2003, p.1366). Further on they additionally state: “Innovative performance in the narrow sense refers to results for companies in terms of the degree to which they actually introduce invention into the market, i.e. their rate of introduction of new products, new process systems or new devices.” (Hagedoorn and Cloodt, 2003, p.1367). This corresponds with the distinction we made above between invention and innovation. Further in their article Hagedoorn and Cloodt discuss the differences and overlap between inventive and innovative performance and they conclude with the discussion and testing of single versus multiple indicators regarding innovative performance.

The use of patent counts as an indicator for inventive or innovative performance is still the topic of an extensive discussion. However even critical authors admit that patent counts can be an appropriate indicator (Hagedoorn and Cloodt, 2003). The problem with counting individual patents is that, especially when the patent portfolios are larger, tend to contain a lot of similar patents protecting the same invention in different countries. With this in regard, counting individual patents may still be valid when considering innovative performance or evaluating the perceived value of an invention. In essence the problem is that alone, the quantity of patents is not a great indicator for performance. However, because this information is readily available geographically as well as historical it is being used cautiously for this
Figure 2: Schematic curve of number of citations versus paper number, with papers numbered in order of decreasing citations. The intersection of the 45° line with the curve gives h. The total number of citations is the area under the curve. Hirsch (2005)

purpose.

One of the problems when using patents to assess performance is that the quantity of patents is only relevant in regard to their quality. The problem with poor patents is that they do not offer the intended protection, they are easily circumvented or do not hold up in court. Because of this, the patent is worthless and it only costs money. To control for this, the quality of a patent needs to be included in the evaluation of a patent portfolio.

Another principle of patents is the idea of Quid pro quo, meaning that you do not get anything for nothing. The idea behind this is that although an inventor gets an exclusive right to commercialize his invention, the invention does get published. As a result, anyone can see the invention, but they are prohibited to exploit it commercially. They can however build upon or circumvent it. This results in that pivotal patents are used as a starting point for other inventions that may lead to a patent. In the article of Harhoff et al. (1999) they use citations as a measuring instrument in an attempt to learn something about the value of patented inventions. Depending on national practice, citations are placed in the patent text to show how it is different from the prior art. Harhoff et al. (1999) al state: “For one, it is reasonable to suppose that the prior inventions cited in new patents tend to be the relatively important precursors that best define the state of the art.”

And: “Second, because prior inventions set the stage for new inventions, citations are used to measure a potentially important economic externality, i.e., the impact the knowledge embodied in prior inventions has in stimulation new contributions.” (Harhoff et al., 1999, p. 511). Although Harhoff et al. (1999) continue to research the causality between citation frequency and the value of patented inventions, it is reasonable to assume that if patents are more frequently cited the inventions are more important.

The field that analysis publications is called bibliometrics and when it is specifically concerning scientific literature, it is called scientometrics. One of the subjects they are engaged in is the analysis of scientific publications to assess the productivity, quality and impact of publications and scholars. The analysis of patents and citations is quite analogue to this and that is why we looked for some insights and indicators in this field. One interesting index that measures the productivity and impact from scholars is the Hirsch-index (h-index). The h-index is proposed by Hirsch (2005) as a particularly simple and useful way to characterize the scientific output of a researcher. The h-index is defined as followed: A scientist has index h if h of his or her \( p \) papers have at least \( h \) citations each and the other \( (N_p - h) \) papers have \( \leq h \) citations each. This can be graphically represented as can be seen in figure 2. The strength of he h-index is that it combines a quantity
and a quality indicator into a single comparable value. Hirsch developed the h-index to characterize scientific output of researches; however, it can also be used to analyze the impact of an organization's patent portfolio as shown by Guan and Gao (2009) in their article, *Exploring the h-index at patent level*. In the article, Guan applies the h-index to patents where the patent h-index is defined as follows: For a general group of patents, h is such that h patents received at least h citations from later patents, while other patents received no more than h citations. Only patent to patent citations are counted, non-patent references (NPR) are not regarded. This is because a citation from another patent can be seen as a "vote" from the referencing patent to the referred patent, as such NPR can be seen as votes for oneself. Guan compares the patent h-index to other technological indicators and concludes the following: "This confirms that on one hand, similar to citation counts, the patent h-index does reflect the importance or impact of patents; on the other hand, unlike citation counts, the patent h-index balances the quantity (number of patents) and the quality (citations) of patents for an assignee in a reasonable way. In summary, the above findings show that the patent h-index is indeed an effective indicator for evaluating the technological impact or quality of an entity." The patent h-index thus is a suitable performance indicator to assess the inventive impact of an organization's patent portfolio.

5. Propensity to Patent

For a performance indicator to have any meaning it is necessary that it is compared to the performance indicator of other organizations. This way we can attempt to analyze the characteristics that lead to the difference in performance. The framework created in this article with the patent maturity typology as an independent variable and the patent h-index as a dependent variable works in the same way. A higher score on the patent h-index is expected for more mature and active organizations (figure 3). When comparing the PMM and patent h-index of organizations, we hope to explain the differences in their patent h-index score by the differences in their PMM. The connecting element between these variables are the patents. With a higher PMM score we expect the patent output to rise in quantity and quality, leading to a higher patent h-index. In this case the patents are regarded as a sample of the inventive output of the organization. When doing this the assumption is made that patents are a representative sample of the inventive output. The question arises if this assumption can be made and can be generalized to other organizations. Unfortunately, most likely this is not the case. When we look to the literature regarding the use of patent statistics, different variables are discussed that can cause a bias. These variables will have, direct or indirect, an influence on the Propensity to Patent (P2P) of an organization. In essence, this means that the size and composition of the patent portfolio will vary between organizations. Figure 4.

Propensity to patent is not a new concept. Scherer (1965) already used it to describe the limitations of counting patents for an inventive index. Scherer (1965) measured P2P by looking to the differences in patent output per unit of engineering input. A multitude of researchers use different definitions, applications and measurement methods. As might be expected it is difficult to compare the inventive impact of a mining company and a pharmaceutical company, largely because of the differences in the industry sector. We are going to use P2P as a construct that consists of uncontrollable external forces that influence the quantity and quality of the patents, most notably industry sector and firm size.

The best way to evaluate the PMM's is to use a homogeneous sample; firms in the same industry and of approximately the same size. However this is not always possible or desirable for the researcher. When a heterogeneous sample cannot be avoided, P2P can be used as an intervening variable to correct for the differences.

6. Conceptual model

With the introduction of P2P we can now construct the complete model. In figure 5 there is a schematic overview of the conceptual model. The PMM is the independent variable with four modes, ranked ordinal. It has a direct positive effect on the inventive impact which is measured using the patent h-index. If necessary the P2P can be used as an intervening variable, positively influencing the effect of PMM on the inventive index.

7. Operationalization

With the model now complete we can operationalize it so the necessary data can be collected. First
Figure 3: A possible course of the patent h-index related to the patent management maturity

Figure 4: The influence of P2P on the sample
the PMM needs to be established. This will be done by using a questionnaire, as has been done by Kern and van Reekum (2012).

Secondly it needs to be established if we are working with a homogeneous or heterogeneous sample. When it is the latter it will be necessary to establish the P2P rates of the sample organizations and their industry sectors. Because of the sector wide information needed it is unpractical to do a own survey for this, however existing surveys exist that report some results regarding the P2P. Good examples are the research of Arundel and Kabla (1998) using the MERIT/SESSI data and the research of Brouwer and Kleinknecht (1999) using the CIS micro data. At last the h-index needs to be determined. This can be done by using the Derwent Innovation Index as has been done by Guan and Gao (2009). We will elaborate on the gathering of this data.

7.1. Derwent Innovation Index

The Derwent Innovation Index is accessible as an on-line database through web of knowledge from Thomson Reuters. It covers 40 worldwide patent issuing authorities covering over 14.3 million inventions dating back to 1963. Using the Derwent Innovation Index and the instructions from Guan and Gao (2009) it is simple to determine the patent h-index of an assignee. All the patents of an assignee during a given time span can be retrieved up to the date of accessing the database. These patents can be sorted according to the number of citations they have, making it possible to find the patent h-index of the portfolio. Alternatively this list can be plotted together with a 45° line \((y = x)\) in a graph. The intersection between the two marks the patent h-index score, rounded down to the lowest integer. An example of such a plot can be seen in figure 6.

Using the Derwent Innovation index we determined the h-index of the 19 biotechnological and biopharmaceutical organizations that where the subject of the pilot and case study of van Reekum (1999). In table 4 the patent h-index is shown accompanied by the total number of patents and citations.

8. Discussion

Continuing with the information from the Derwent Innovation Index, we put it besides the Patent Management Maturity scores found in the pilot and case study of van Reekum (1999). We looked if there was any correlation between the h-index and the PMM, unfortunately no correlation was found. Although this is unfortunate, it was more or less expected. The time lag between the determination of the PMM and patent h-index score is almost 14 years and although most literature regarding patent statistics plead to take account for one Holger (2001), it is safe to say that 14 years is to long. During these 14 years the management practice of these organization most like also changed, meaning that the current state of their patent portfolio and thus patent h-index is a reflection of the management of more recent years. Another indicator for this is that most of the patents are granted in last five years. However, there is something to learn from these results. We can consider it as a test case where we have shown that the patent h-index can be used as a indicator for small-medium enterprises and that it is not only applicable to large multinationals as Guan and Gao (2009) showed. From the results in table
Figure 6: Determining the patent h-index graphically.

<table>
<thead>
<tr>
<th>Derwent patent assignee code</th>
<th>Total # patents</th>
<th>Total # citations</th>
<th>Patent h-index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crucell CRUL-C</td>
<td>170</td>
<td>1204</td>
<td>18</td>
</tr>
<tr>
<td>Kreatech Biotechnology BV</td>
<td>KREA-N</td>
<td>15</td>
<td>103</td>
</tr>
<tr>
<td>Pharmatarget BV</td>
<td>PHAR-N</td>
<td>6</td>
<td>142</td>
</tr>
<tr>
<td>Pantarhei Bioscience</td>
<td>PANT-N</td>
<td>75</td>
<td>75</td>
</tr>
<tr>
<td>River Diagnostics</td>
<td>RIVE-N</td>
<td>10</td>
<td>41</td>
</tr>
<tr>
<td>AM-Pharma</td>
<td>AMPH-N</td>
<td>12</td>
<td>27</td>
</tr>
<tr>
<td>Axon Biochemicals BV</td>
<td>AXON-N</td>
<td>4</td>
<td>21</td>
</tr>
<tr>
<td>PhotoBioChem NV</td>
<td>PHOT-N</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>Amsterdam Molecular Therapeutics</td>
<td>AMST-N</td>
<td>19</td>
<td>9</td>
</tr>
<tr>
<td>Mucovax</td>
<td>MUCO-N</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Phytovation BV</td>
<td>PHYT-N</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Genetwister Technologies BV</td>
<td>GENE-N</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Agenda</td>
<td>AGEN-N</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>Mubio Products BV</td>
<td>MUBL-N</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Pharming Group NV</td>
<td>PHAR-N</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Bioceros BV</td>
<td>BIOC-N</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Hep-Art Medical Devices BV</td>
<td>HEPA-N</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Meddens Diagnostics BV</td>
<td>n.a.</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C-Tres BV</td>
<td>n.a.</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>n.a.</strong></td>
<td><strong>17,89</strong></td>
<td><strong>86,95</strong></td>
</tr>
</tbody>
</table>

Table 4: The total number of patents, citations and the h-index. As retrieved from the Derwent Innovation Index on 31-5-2013
we can also conclude that the patent h-index has distinctive properties compared to counting patents and/or citations, because as table 4 clearly shows, the most patents and/or citations do not directly translate to the highest h-index. Additionally it also accentuates the differences between portfolio’s of approximately the same size.

One of the biggest problems in research where patent data is used as measurement, is that the researcher makes reservations on the use of patents as data, but still continues using the data as if real reservations had not been made (Basberg, 1987). The use of patents as data has inherent weaknesses we have to account for, using the patent h-index may be a good way to remedy some of this issues. Nevertheless, what Schmookler wrote in 1966 still is very true: “We have a choice of using patent data cautiously and learning what we can from them, or not using them and learning nothing about what they alone can teach us (Schmookler, 1966, p. 56).”

References


